IQuity’s Breakthrough Autoimmune Technology
IQIsolate® is a suite of algorithms utilizing machine learning methods that analyze expression of RNA markers detected in a simple blood sample. IQuity has applied this approach to neurology, gastroenterology and rheumatology, three specialties that serve a majority of autoimmune patients.
IQuity’s technology, IQIsolate analyzes RNA expression data from a blood sample to identify the presence or absence of disease at the cellular level. RNA expression is representative of presence of disease in real time, while changes in DNA indicate potential risk of disease. IQIsolate can distinguish among diseases in a given specialty – the gastroenterology panel can distinguish between irritable bowel syndrome (IBS) and inﬂammatory bowel disease (IBD). Within IBD, this technology can accurately distinguish Crohn’s from ulcerative colitis. The IQIsolate process takes one week and delivers results with greater than 90% accuracy.
IQuity is ﬁrmly committed to data transparency and scientiﬁc peer review, and will perform its tests in its independent CLIA certiﬁed lab.
“Multiple Sclerosis (MS) remains a clinical diagnosis, and the certainty of the diagnosis is enhanced by imaging and electrodiagnostic studies. Any test which will increase the certainty of an MS diagnosis is of value to the treating physician. The results are likely to influence both making the diagnosis of MS and in implementing therapies that benefit the patients.”
Subramaniam Sriram, MD,
Director, MS Center,
Vanderbilt University Medical Center